News
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry ‘This kid died from the same thing we’re trying to fight off right now,’ one parent says ...
FDA says it implored Sarepta to do a study where some patients are randomly assigned to get a placebo, but it didn’t. Eteplirsen only works in Duchenne patients with a particular type of genetic ...
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular ...
A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months. Like the ...
WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular ...
The FDA has approved a Sarepta Therapeutics drug for Duchenne muscular dystrophy, clearing the way for the company to commercialize its third therapy for the rare, muscle-wasting disease.
Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental treatment for Duchenne muscular dystrophy, meaning that it ...
Hosted on MSN1mon
Sarepta reports outcomes from trial of Duchenne muscular ... - MSNLast December, Sarepta completed enrolment and dosing for the Phase III EMERGENE trial of SRP-9003 (bidridistrogene xeboparvovec), targeting limb-girdle muscular dystrophy Type 2E/R4. "Sarepta ...
Sarepta Therapeutics convinced a Delaware federal court on Friday to end a patent lawsuit filed by biotech company Regenxbio and the University of Pennsylvania over Sarepta's treatment for ...
Jefferies has initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT) at buy saying its Duchenne muscular dystrophy franchise represents a $4B+ opportunity, as well as a strong pipeline and ...
Cambridge-based Sarepta Therapeutics to charge $3.2M for new Duchenne muscular dystrophy treatment. First gene therapy for deadly muscle-wasting disease approved Thursday by FDA ...
Sarepta Therapeutics Inc.SRPT0.08%increase; green up pointing triangle said Tuesday that a peer-reviewed medical journal published the results, some of which had been announced, from a midstage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results